Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03514641 · ClinicalTrials.gov registry record · Phase 2
An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension
A Phase 2 study, sponsored by Theracos.
- Completed
- Registry status
- Phase 2
- Development phase
- 673
- Enrollment target
NCT03514641 is a Phase 2 study that has completed, run by Theracos. The registered enrollment target is 673 participants.
The verdict
NCT03514641, a Phase 2 study, has completed, sponsored by Theracos.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 673 participants
- Enrollment target
Study Summary
This integrated assessment consists of two studies, 603A and 603B, to be carried out sequentially in a common study population. Participating subjects informed of the trial design and their consent to participate in both studies were to be obtained in a single consent form. Approximately 680 male or female adult subjects were to be enrolled.
Interventions
- DRUG Placebo
- DRUG Bexagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 673 participants |
| Start Date | 2017-10-18 |
| Est. Completion | 2018-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03514641
The ClinicalTrials.gov registry entry for NCT03514641 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 673 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theracos, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03514641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03514641 about?
NCT03514641 is a clinical study titled "An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension". This integrated assessment consists of two studies, 603A and 603B, to be carried out sequentially in a common study population. Participating subjects informed of the trial design and their consent to participate in both studies were to be obtained in a single consent form. Approximately 680 male or...
What is the current status of trial NCT03514641?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 673 participants. The study started on 2017-10-18. Estimated completion is 2018-11-30.
What interventions are being tested in trial NCT03514641?
The interventions under investigation include: Placebo (DRUG), Bexagliflozin (DRUG).
Who is sponsoring clinical trial NCT03514641?
This trial is sponsored by Theracos, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.